NSE: CIPLA | BSE: 500087

Strong Performer, Getting Expensive

Download real time

1572.00 39.50 (2.58%)

4.0M NSE+BSE Volume

High volume today

NSE 28 Jul, 2025 3:31 PM (IST)

126,978.5

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Target Upgrade

Nuvama maintains a 'Hold' rating on Cipla; raises the target price to Rs 1,651 See details

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Cipla Ltd.

16 Aug 2016

1572.00

2.58%

Cipla Q1FY17 Update 16Aug2016

Neutral: Cipla Ltd.

Target

Phillip Capital

Key highlights: Revenues grew 10% yoy at Rs35.94bn despite the integration of Invagen and that was 9% below our estimates. The miss in revenues was primarily due to no visible growth in Invagen portfolio, muted domestic as well as South African business. The margin performance at 17% (6.7% in Q4FY16) was almost in line of our expectations of 16.2% but the EBITDA missed our estimate by 4% due to lower sales.Thanks to lower tax incidence of 16% (vs 23% normal) that helped it report PAT of Rs 3.65bn (4% below estimated Rs 3.52bn). At a normalised tax rate, the profit performance was 7% below estimate. Phillip Capital retain their Neutral rating with lowered TP of Rs485.

Cipla Ltd. has an average target of 1702.12 from 8 brokers.

Cipla Ltd.

13 Aug 2016

1572.00

2.58%

Cipla: Weak top line across markets; recovery in margins the key

Neutral: Cipla Ltd.

Motilal Oswal

US impacted by high base; regulatory actions in India; currency volatility in EM: Although US base business (ex Nexium and Invagen) grew >30% YoY, overall US sales declined 26% YoY to USD98m. CIPLA expects the US portfolio to deliver robust growth on the back of its strong launch pipeline (~15 launches expected in rest of FY17) and enhanced focus on R&D.; Domestic formulation sales grew 5% YoY in 1QFY17 (~2% impact due to regulatory issues). According to IMS, secondary sales grew ~13% in 1Q. South Africa business grew 22% YoY in constant currency, but...

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

12 Aug 2016

1572.00

2.58%

Cipla - 1QFY17 Result Update

Hold: Cipla Ltd.

Target

Reliance Securities

Cipla's Sales, EBITDA & PAT stood at Rs36.9bn, Rs7.1bn & Rs4.6bn, respectively in 1QFY17. It reported lower growth on all fronts on account of high base effect (Nexium contribution at ~US$75mn) in 1QFY16. Domestic formulations business (40% of sales) declined 4% yoy to Rs14.5bn due to NLEM and ban on Fixed Dose Combinations. Negligible contribution from Nexium impacted growth in export formulations (-7% yoy), which is partially offset by full quarter consolidation of Invagen business (contribution US$55mn). EBITDA margins declined 785bps to 19.1% yoy due to Nexium contribution in 1QFY16, higher R&D; cost (6.6% of sales vs. 4.4% of sales in 1QFY16) and employee...

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

17 Jun 2016

1572.00

2.58%

Roadmap to doubling sales by 2020

Cipla Ltd.

Motilal Oswal

Focus on high-yielding assets more than ever We arranged a board room meeting with Mr. Subhanu Saxena (Global CEO and Managing Director, Cipla Ltd) and more than 20 senior investors. Mr. Subhanu...

Axis Direct released a Buy report for Cipla Ltd. with a price target of 1700.0 on 28 Jul, 2025.

Cipla Ltd.

10 Jun 2016

1572.00

2.58%

Cipla Ltd

Neutral: Cipla Ltd.

Angel Broking

Cipla's results for 4QFY2016 have come much below our expectations. Sales came in at Rs3,207cr V/s Rs3,274cr expected, a yoy growth of 7.6%. The sales growth was driven by domestic formulations (Rs1,258cr), as expected, which grew 15.9% yoy, while exports posted a yoy growth of 7.4%. On the operating front, the EBDITA came in at 5.0% V/s ..

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

25 May 2016

1572.00

2.58%

Cipla

Hold: Cipla Ltd.

Recommendation Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 5.6% YoY to | 3267 crore, (I-direct estimate: | 3196 crore) on account of 15.8% growth in domestic formulations to |...

Axis Direct released a Buy report for Cipla Ltd. with a price target of 1700.0 on 28 Jul, 2025.

Cipla Ltd.

25 May 2016

1572.00

2.58%

Cipla Q4FY16 Update 25May2016

Neutral: Cipla Ltd.

Recommendation Target

Phillip Capital

8 Gross disappointment in operating performance with 12% miss in revenues and 1160bpsvesurpriseinEBITDAmarginresultingina79%missinPATestimates 8 Oneoffadjustments(pertainingtoinventorywriteback,businessrationalisationin...

Cipla Ltd. has an average target of 1702.12 from 8 brokers.

Cipla Ltd.

04 Mar 2016

1572.00

2.58%

Master Pick-Cipla Ltd

Cipla Ltd.

Religare

Cipla has increased its R&D expenditure as a percentage of sales from six per cent a year before to eight per cent now to focus more on US markets. The company is looking at three to four filings a quarter in the US (20 over the next one year) and expects FY17 to see good traction in the world's largest health care market.

Cipla Ltd. is trading above all available SMAs

Is Cipla Ltd. worth buying?

618 Votes:

Buy 75.73%

Sell 14.08%

Hold 10.19%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf